Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 18, 2017 - Issue sup1: Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis (ALS). Guest Editor: Angela Genge
Submit an article Journal homepage
2,937
Views
14
CrossRef citations to date
0
Altmetric
Research Article

A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies

Alexander KalinMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and Correspondence[email protected]
,
Elvia Medina-ParaisoMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Kaoru IshizakiMitsubishi Tanabe Pharma Corporation, Tokyo, Japan
,
Alex KimMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Yannong ZhangMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Takanori SaitaMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
&
Masahiko WasakiMitsubishi Tanabe Pharma Corporation, Tokyo, Japan
 show all
Pages 71-79 | Received 20 Apr 2017, Accepted 27 Jul 2017, Published online: 05 Sep 2017

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Angela Genge & Benjamin Brooks. (2019) Edaravone administration in pivotal clinical Study 19. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:3-4, pages 298-299.
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now

Articles from other publishers (12)

Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
Reza Boostani, Nahid Olfati, Hosein Shamshiri, Zanireh Salimi, Farzad Fatehi, Seyed Arya Hedjazi, Atefeh Fakharian, Majid Ghasemi, Ali Asghar Okhovat, Keivan Basiri, Bahram Haghi Ashtiani, Behnaz Ansari, Gholam Reza Raissi, Seyed Ahmadreza Khatoonabadi, Payam Sarraf, Sara Movahed, Akram Panahi, Bentolhoda Ziaadini, Mohammad Yazdchi, Jalal Bakhtiyari & Shahriar Nafissi. (2023) Iranian clinical practice guideline for amyotrophic lateral sclerosis. Frontiers in Neurology 14.
Crossref
Gholamreza Shamsaei, Fatemeh HoushmandAhmad Ahmadzadeh DeylamiArmita ValizadehShahram RafieMaryam Moradi. (2022) The Efficacy and Safety of Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis: A Pilot Study. Advanced Pharmaceutical Bulletin 13:2, pages 361-367.
Crossref
Purushottam Neupane, Pawan Kumar Thada, Pramod Singh, Abdul Rafae Faisal, Niraj Rai, Prabhat Poudel, Madeeha Subhan Waleed, Jonathan Quinonez, Samir Ruxmohan & Esha Jain. (2023) Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. Cureus.
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Hideaki Matsuda, Yuichiro Kato & Manabu Hirai. (2022) Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clinical Therapeutics 44:12, pages 1552-1565.
Crossref
Angela Genge, Benjamin Rix Brooks, Björn Oskarsson, Alexander Kalin, Ming Ji, Stephen Apple & Laura Bower. (2022) Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch. Drugs in R&D 22:3, pages 205-211.
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Hidetoshi Shimizu, Shinsuke Inoue, Mai Endo, Yoshinobu Nakamaru, Kaori Yoshida, Tomoko Natori, Masae Kakubari, Makoto Akimoto & Kazuoki Kondo. (2020) A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects. Clinical Pharmacology in Drug Development 10:1, pages 46-56.
Crossref
Masha G. Savelieff, Geewoo Nam, Juhye Kang, Hyuck Jin Lee, Misun Lee & Mi Hee Lim. (2018) Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chemical Reviews 119:2, pages 1221-1322.
Crossref
Alex G. Karanevich, Luke J. Weisbrod, Omar Jawdat, Richard J. Barohn, Byron J. Gajewski, Jianghua He & Jeffrey M. Statland. (2018) Using automated electronic medical record data extraction to model ALS survival and progression. BMC Neurology 18:1.
Crossref
Magdalena Kuźma-Kozakiewicz. (2018) Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 52:2, pages 124-128.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.